Company intelligence / Profile preview
Dimerix
Fitzroy, Austrailadimerix.com ↗
- Ownership
- Public · DXB
- Development stage
- Other
01
Overview
Dimerix’s lead asset, DMX‑200, is in a Phase 3 clinical trial for focal segmental glomerulosclerosis. Interim results from the ACTION3 study showed positive efficacy signals in reducing proteinuria compared to placebo. The company also has a preclinical program in COPD and additional indications under investigation.
- Therapeutic areas
- NephrologyPulmonology
- Modalities
- Small moleculePlatform technology (Receptor-HIT)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Dimerix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dimerix.